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Abstract
Background: The Hepatocyte Growth Factor (HGF) is a pleiotropic cytokine involved in many physiological processes,
including skeletal muscle, placenta and liver development. Little is known about its role and that of Met tyrosine kinase
receptor in cardiac development.
Methodology/Principal Findings: In this study, we generated two transgenic mice with cardiac-specific, tetracycline-
suppressible expression of either Hepatocyte Growth Factor (HGF) or the constitutively activated Tpr-Met kinase to explore:
i) the effect of stimulation of the endogenous Met receptor by autocrine production of HGF and ii) the consequence of
sustained activation of Met signalling in the heart. We first showed that Met is present in the neonatal cardiomyocytes and
is responsive to exogenous HGF. Exogenous HGF starting from prenatal stage enhanced cardiac proliferation and reduced
sarcomeric proteins and Connexin43 (Cx43) in newborn mice. As adults, these transgenics developed systolic contractile
dysfunction. Conversely, prenatal Tpr-Met expression was lethal after birth. Inducing Tpr-Met expression during postnatal
life caused early-onset heart failure, characterized by decreased Cx43, upregulation of fetal genes and hypertrophy.
Conclusions/Significance: Taken together, our data show that excessive activation of the HGF/Met system in development
may result in cardiac damage and suggest that Met signalling may be implicated in the pathogenesis of cardiac disease.
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Introduction
The cellular events occurring during the early stages of life,
including pre- and perinatal phases, may have strong impact on
long-term health. Epidemiological and experimental evidences
suggest that development of cardiovascular diseases in the adult is
influenced by stressful events during late prenatal or early
postnatal life [1]. A correlation between infant mortality and the
incidence of cardiovascular disease was first reported in 1977 and
lead to the Barker’s hypothesis of the fetal origins of increased risk
of cardiovascular disease [2]. The fetal origins hypothesis of Barker
states that programming during fetal life occurs in response to an
adverse environment and results in permanent adaptive responses
that lead to structural and physiological alterations and the
subsequent development of cardiovascular disease. Although this
hypothesis was originally proposed in the context of intrauterine
growth, it has been extended to the important environmental
transition which occurs between plastic phase of development and
mature post-plastic phase. In rodents, transition of cardiomyocytes
from hyperplasia to hypertrophy growth occurs during the first
week of postnatal period [3]. In parallel with this transition,
murine cardiomyocytes accumulate contractile proteins and
undergo changes in troponin I (TnI) and myosin heavy chain
(MHC) isoform expression. The cardiac TnI (cTnI) and the slow
skeletal TnI (ssTnI) transcripts coexist in the developing heart
throughout fetal and perinatal stages and then cTnI completely
replaces ssTnI in the adolescent mouse [4,5]. Concurrently, a-
MHC completely replaces b-MHC in the ventricles, becoming the
dominant isoform (.90%) in the adolescent mouse [6]. Besides
myofibrillar content, important cell-shape changes occur in
cardiomyocytes during early postnatal development, with progres-
sive polarization of the cardiomyocyte and restriction of the
intercalated disc-associated proteins to the bipolar ends of
cardiomyocytes [7].
The Hepatocyte Growth Factor (HGF) is a mesenchyme-
derived multifunctional molecule that elicits mitogenic and
morphogenic activities in development, as well as in many
patho-physiological processes [8]. The HGF receptor has been
identified as the Met tyrosine kinase, the product of the met proto-
oncogene, which is expressed in a variety of cell types, such as
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epithelial, endothelial and mesenchymal cells. Upon HGF
binding, Met undergoes autophosphorylation on several tyrosine
residues and constitutes a multifunctional-docking site for adaptor
proteins containing the SH2 motif. Recruitment of these molecules
results in the activation of several downstream signalling cascades,
such as Ras-Raf-MEK-ERK and PI3K pathways, which are
essential for HGF-induced cellular changes, that collectively give
rise to a complex morphogenetic program known as ‘‘invasive
growth’’. This program involves cell spreading, cell-cell dissociation,
migration, invasion, proliferation and differentiation. Notably,
during the various phases of this process, cells result protected
from apoptosis [9].
In the heart, HGF has been shown to exert anti-apoptotic/
cardioprotective effects in rats subjected to myocardial infarction
[10,11]. It has also been suggested to have a role in cardiac
regeneration after myocardial infarction [12]. Met is only weakly
expressed in adult cardiomyocytes, but both HGF and Met
mRNA are induced following heart injury [10,11]. The beneficial
effect of HGF in the damaged heart has been documented in
experimental models. Despite the clear indications for HGF to
effectively treat post-ischemic heart failure, the knowledge on the
role of the HGF/Met system in normal cardiac development is still
limited. A few reports have shown expression of HGF/Met in the
heart during very early embryonic development [13,14], whilst
studies investigating their expression and function in the heart
during late prenatal or early postnatal life are still missing. In
particular, nothing is known about the role of the HGF/Met
system in the establishment and maintenance of the balance
between proliferative and differentiating events during postnatal
heart development, which may lead to hyperplastic and hyper-
trophic growth, respectively.
In this study, we aimed to investigate this issue by activating the
HGF/Met system specifically in the heart. To this purpose we
generated two novel gain-of-function transgenic models with
tetracycline-suppressible expression of either HGF or activated
Met under control of the a-MHC promoter. In the mouse embryo,
the a-MHC promoter is expressed throughout the myocardium
starting from E8 [6]. By E12.5, a-MHC is robustly expressed in
both left and right atria. However, transcripts are more abundant
in the right than the left ventricle. Expression in the right ventricle
is also downregulated with respect to that in the atria. At E14.5
and E16.5, a-MHC gene is strongly expressed in both atria, while
in the ventricles it retains a right dominant profile. At birth, a-
MHC transcript levels start increasing and, by postnatal day 3, a-
MHC is upregulated in both the right and the left ventricle [15].
Thus, the a-MHC promoter is especially useful for analyzing the
effect of transgenic protein during the prenatal and postnatal
period of rapid heart growth. In the HGF model, autocrine
production of HGF stimulated the activation and physiological
downregulation of endogenous Met receptor. In the model of Met
activation, the intracellular signal stemmed from ligand-indepen-
dent and constitutive stimulation of Met kinase in cardiomyocytes.
We show that even transient increases in HGF/Met signalling
during development can lead to cardiac pathology, due in part to
sustained downregulation of Cx43.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Ethical Commis-
sion of the University of Torino, Italy, and by the Italian Ministry
of Health, both of which accepted the use of mice for this study
(A/R 0045 and A/R 0041).
Conditional cardiac HGF tg mice
The mouse HGF cDNA was cloned into the pBI-EGFP plasmid
which is responsive to tTA transactivator [16]. The construct was
linearized with AseI and a 6.1-kb gel-purified fragment was
microinjected into the fertilized eggs of FVB mice in the San
Raffaele-Telethon Core Facility for Conditional Mutagenesis
(Milan, Italy). Founder mice were identified as described [17]. A
transgenic line (HGF-TRE-GFP responder) was bred with the a-
MHC-tTA mouse (kindly donated by Dr. G. Fishmann [18]) and
double heterozygotes were studied under one of three conditions:
(1) Mice were never administered Doxycycline (DOX, Sigma), so
that HGF was expressed in the prenatal and postnatal period
(HGF tg mice). (2) Pregnant mothers and suckling progeny
received DOX (200 mg/ml in drinking water with 3% sucrose) to
continuously repress HGF (HGF + DOX tg mice). (3) Pregnant
mothers were not administered DOX to induce HGF in utero and
suckling progeny and weaned pups received DOX to repress
exogenous HGF after birth (prenatal HGF tg mice).
Conditional cardiac Tpr-Met mice
The Tpr-Met-TRE-GFP responder mouse [17] was bred with
a-MHC-tTA mouse and double heterozygotes were studied under
one of two conditions: (1) Mice were never administered DOX
(Tpr-Met mice). (2) Pregnant mothers received DOX throughout
gestation and DOX was removed at P1 to induce Tpr-Met after
birth (postnatal Tpr-Met mice). Control mice consisted of
identically treated littermate wild-type mice for both transgenic
models.
Real-time PCR and Semi-quantitative RT-PCR
Hearts were excised, rinsed in ice-cold Tyrode solution and
prepared in RNA later (Ambion). Total RNA was extracted with
TRIzol (Sigma). Qiagen RNAeasy kit (Qiagen GmbH, Hilden,
Germany) was used to enhance purification. After quantification
(NanoDropH ND-1000, NanoDrop Technologies), reverse tran-
scription was performed using DNA Polymerase/Superscript III
Reverse Transcriptase (Invitrogen). For Real-time PCR, primers
and Taqman probe specific for the transgene were designed using
the File builder 3.1 program (Applied Biosystems, Foster city, CA,
USA). Real-time PCR was performed on a 7300 Real-time PCR
instrument (Applied Biosystem). Sample reactions were performed
in triplicate and normalized to 18S mRNA expression. For semi-
quantitative RT-PCR, control samples were prepared without
adding the RT enzyme to the reaction. Tubulin was used as
control. See Table S1 for primers used.
Western blot - Protein extracts from heart ventricles were
prepared using RIPA buffer added with Protease Inhibitor
Cocktail (Sigma). Heart lysates were subsequently sonicated and
centrifuged at 14000rpm (259 at 4u). Protein concentration was
determined by Bio-Rad protein assay. Protein lysates (5 mg or
100 mg for Met protein) were separated by SDS-PAGE,
transferred to nitrocellulose membrane Hybond-C-extra (Amer-
sham) and blotted with primary antibodies and then with
horseradish peroxidase-conjugated secondary antibodies (Amer-
sham). Proteins were revealed by enhanced chemiluminescence
SuperSignal detection reagents (Pierce) and quantified with GS800
model Bio-Rad (Figures 3,4) and ImageJ (rsb.info.nih.gov/ij)
(Figures 2,6).
Stereomicroscopy, Immunofluorescence (IF) and
Confocal Analysis
Hearts were removed, rinsed in ice-cold Tyrode solution and
fixed in 4% paraformaldehyde (PAF) in phosphate-buffered saline
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(PBS) for 4 hours at 4uC. After PBS washings, hearts were
incubated in 30% sucrose in PBS overnight at 4uC to preserve
GFP fluorescence. Stereomicroscopy was viewed by Leica MZ12
and imaged by Evolution VF colour cool camera and Image-Pro
Plus software. Tissues for indirect immunofluorescence were
embedded in OCT (Biooptica), quickly frozen in isopentane and
stored at 220uC. Sections were 20 mm cut, post-fixed 59 in ice-
cold 4% PAF and washed with PBS. For Met staining, sections
were incubated with SP260 primary antibody (Santa Cruz)
overnight at 4u and subsequently with Alexa Fluor 546-conjugated
goat anti-rabbit antibody (Molecular Probes) for 1h at room
temperature. The double overlay pictures (Met/GFP) were viewed
with a Leica DM6000 CS confocal microscope. Optical slices
(1024 by 1024 pixels, frame resolution) were acquired at 10Hz and
processed with LAS AF software (Leica Microsystems CMS
GmbH). Quadruple overlay pictures (Laminin/Griffonia/DAPI/
GFP) were obtained by staining with rabbit polyclonal antibody
laminin (Sigma) followed by Alexa Fluor 647-conjugated goat anti-
rabbit antibody (Molecular Probes), two hours incubation with
rhodamine Griffonia Simplicifolia (Vector Laboratories) and
5 min with DAPI. Quadruple overlay pictures (Cx43/a-actinin/
DAPI/GFP) were obtained by staining with rabbit polyclonal
antibody Cx43 (Sigma) and mouse monoclonal antibody a-actinin
(Sigma) and subsequently with Alexa Fluor 647-conjugated goat
anti-rabbit antibody and Alexa Fluor 546-conjugated goat anti-
mouse antibody (Molecular Probes). Confocal microscope imaging
was performed with Leica TCS SP2 AOBS upright microscope.
Optical slices (1024 by 1024 pixels, frame resolution) were
acquired at 200 Hz, with a line average of 8, and processed with
LAS AF software (Leica Microsystems CMS GmbH).
Proliferation evaluation
Ki67 positive nuclei were immunostained in 20 mm thick heart
sections. Primary rabbit polyclonal Ki67 antibody (Novocastra)
and secondary Alexa Fluor 546-conjugated goat anti-rabbit
antibody (Molecular Probes) were used. Fluorescence imaging
and processing were performed with Leica DM6000 CS confocal
microscope and LAS AF software, respectively. 5 fields per area
(Right Ventricle, Left Ventricle and Interventricular Septum) per
mouse were analyzed. 3 mice per group were considered.
H9c2 cell proliferation assay
H9c2 cell line purchased from the American Type Culture
Collection was grown as described [19]. 4000 cells/cm2 were
seeded. Adhesion medium was replaced with fresh medium
containing 10 U/ml of HGF for 24h and 48h. AlamarBlueTM
(Invitrogen) assay was performed according to manufacturer’s
instructions. For BrdU assay, cells were seeded on coverslips and
incubated with 10 mm BrdU (Sigma) for 24h, together with
treatment. Cells were fixed with 4% PAF, permeabilized with
0.1% tween, treated with 2 M HCl for 1h and stained with BrdU-
specific antibody (Sigma) and Alexa Fluor 488-conjugated goat
anti-mouse antibody (Molecular Probes). Propidium iodide was
used for nuclear staining. Fluorescence imaging and processing
were performed with Leica DM6000 CS confocal microscope and
LAS AF software, respectively. All images were taken with the
same parameters of exposition and processed after conversion in
8bit grayscale. Stained nuclei were counted using ImageJ. A
minimum cut-off for intensity and particle size was established.
Nuclei on border edges were excluded. 7 fields per sample and 2
replicates were considered.
Antibodies
See Supplemental Table S2 for a list of antibodies used.
Lucifer yellow Assay
Gap junction permeability assay was performed as described
[20] with minor modifications. The ventricle was incubated in
buffer containing Lucifer yellow (2.5 mg/ml) and rhodamine-
conjugated dextran (2.5 mg/ml), which was continuously bubbled
with O2, for 209 at 37uC. Then, the ventricle was fixed with 4%
PAF. The area stained with Lucifer yellow but not with
Rhodamine red was used as an index of gap junction
communication. Short incubation and bubbling with oxygen were
performed to prevent anoxic effects on cellular permeability.
Images were obtained by classical microscopy analysis (Leica
DMRE microscope) of both ventricles. Data from 15 data
sampling were averaged for each of 4 fields per mouse. 3 mice
per group were analyzed.
Histological Analysis and Fibrosis Evaluation
Hearts were rinsed in PBS, dehydrated and embedded in
paraffin. Sections (6–8 mm thick) were rehydrated, stained with
hematoxylin-eosin or Masson’s trichrome and analyzed with Leica
DMRE microscope.
CSA
3 mice per group were analyzed. Transversal 20 mm thick cryo-
sections of the middle region of the hearts were stained with
rhodamine Griffonia Simplicifolia and rabbit polyclonal antibody
laminin and subsequently with Alexa Fluor 488-conjugated goat
anti-rabbit antibody (Molecular Probes) and DAPI. Fluorescence
images were taken at 406magnification with Leica DM6000 CS
confocal microscope and LAS AF software was used for
processing. 15 cross sectional areas of 6 fields per heart were
measured. Small, medium and large-sized fibers were equally
considered. Fiber CSA delimited by laminin staining was
measured using ImageJ software. Density probability distribution
curves were generated.
Cx43 quantification
Images were obtained by classical microscopy analysis (Leica
DMRE microscope) of ventricles and interventricular septum at
206. Data from 10 samplings were averaged for each heart. 6
controls and 3 transgenics were analyzed. Signal intensity of staining
was calculated as percentage of total tissue area using ImageJ.
Echocardiography
Size and function of the left ventricle of the mice were evaluated
by high-resolution echocardiography. M-mode examinations were
performed using a dedicated small-animal high-resolution imaging
unit (Vevo 770; VisualSonics, Toronto, Canada) and a 40-MHz
high-frequency linear transducer (RMV 707B; VisualSonics,
Toronto, Canada). Mice were kept anesthetized with tribromoeth-
anol (Avertin, 350 mg/kg). Real-time imaging was performed with
a frame rate of 100 Hz (temporal resolution of 10 msec). The
following parameters were measured: systolic and diastolic thickness
of the interventricular septum, end-systolic (LVESD) and end-
diastolic diameter (LVEDD) of the left ventricle, systolic and
diastolic thickness of the posterior wall of the left ventricle.
Fractional shortening (FS) was then calculated [21]. The hypertro-
phy index h/r ratio was calculated according to the formula:
h=r~
1=2X IVSTdzPWTdð Þ
1=2LVEDD
All measurements were done on 3 consecutive beats with a stable
heart rate .400 bpm.
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Figure 1. Doxycycline (DOX)-suppressible expression of HGF in the heart. (A) Schematic representation of the two components (a-MHC-tTA
and HGF-TRE-GFP transgenes) for bitransgenic conditional HGF expression. (B) Top: Experimental design: mice were never administered DOX to
express HGF in the prenatal and postnatal period (HGF tg mice); pregnant mothers and suckling progeny received DOX to continuously repress HGF
(HGF + DOX tg mice); pregnant mothers were not administered DOX to induce HGF in utero and suckling progeny and weaned pups received DOX
Met Signalling in the Heart
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Statistics
Data are expressed as the mean 6 SD. Differences between
groups were determined by independent T-tests (one or two-tailed
T-tests have been used; details in each Figure Legend).
Results
Generation and Characterization of HGF tg Mice
To examine the influence of HGF in normal prenatal and
postnatal cardiac growth, we generated a bitransgenic a-MHC-
driven tetracycline-suppressible system (Figure 1A). The GFP
reporter was chosen as being a convenient tracer of transgene
expression. Bitransgenic mice were conceived and maintained in
the absence of Doxycycline (-DOX) to induce exogenous HGF
expression (HGF tg) during prenatal and postnatal heart growth
(Figure 1B). In parallel matings, pregnant mothers were given
DOX starting from conception, throughout pregnancy and
breastfeeding period (HGF + DOX tg). qRT-PCR was performed
on exogenous and total (endogenous + exogenous) HGF mRNA in
prenatal (E16.5) and neonatal (P7) hearts from uninduced (HGF +
DOX tg) and induced (HGF tg) mice. Exogenous HGF mRNA
could be detected only in HGF tg mice kept without DOX, but
not in DOX-treated animals, both at E16.5 and at P7. Liver tissue
was used to confirm specificity of primers for HGF transgenic form
(Figure 1C, upper graph). Since primers for total HGF recognize
both the wild-type and the transgenic forms, the quantification for
uninduced mice refers specifically to endogenous HGF, while data
from induced mice must be observed also considering transgenic
HGF expression. Figure 1C shows that endogenous HGF was
undetectable at embryonic day 16.5 and was still absent at
postnatal day 7. Liver from neonatal HGF tg mice provided the
positive control (Figure 1C, lower graph). Measurement of protein
levels of HGF and GFP confirmed that the transgenes were not
expressed in HGF + DOX tg animals, indicating a tight control of
Tet-Off system of expression (Figure 1D).
Neonatal heart of HGF tg showed specific GFP expression
(Figure 1E, middle and left panels; control at left and HGF tg at
right). Expression of the transgene was heterogeneous in
cardiomyocytes and variable between sibling mice, ranging from
20 to 50% of the cardiomyocytes in the left ventricle (Figure 1E,
right panel). Bitransgenic HGF tg mice were born with the
expected mendelian ratio and showed phenotypically normal
hearts (Figure 1E and Figure S1).
In a cohort of animals (prenatal HGF tg mice), DOX was
administered to suckling progeny 1 day after birth (Figure 1B).
The HGF mRNA was repressed already after 1 day of DOX
treatment (Figure 1F), indicating effective reversibility of the Tet-
Off system.
Met Is Present in Neonatal Cardiomyocytes and
Exogenous HGF Activates its Downstream Effectors
Endogenous Met was localized all around the plasma
membrane of cardiomyocytes in heart tissue isolated from
littermate wild-type animals (control) and, at lower levels of
expression, in HGF tg neonates (Figure 2A). The Met 140-kDa
product (p140Met), clearly detectable in control neonates at P2
and P4, was downregulated at P7 and P18 (Figure 2B). In HGF tg
mice, the level of Met was lower with respect to controls since P2
and it was further downregulated in adolescent mice at P18. Next,
we evaluated whether exogenous HGF activated Met signalling in
neonatal cardiomyocytes (Figure 2C). We found that in HGF tg
mice there was a marked increase in Erk1,2, p38 MAPKs and Akt
phosphorylation with respect to controls (p,0.05). We also tested
the levels of expression and activation of Met signalling in the
H9c2 cardiomyoblast cell line upon addition of recombinant HGF
for various lengths of time (Figure 2D). After 1h of HGF
stimulation, the Met receptor was downregulated. Its level of
expression was recovered after 4h. Erk1,2 and, at lesser extent,
p38 phosphorylation was stimulated 59 after the addition of HGF
and remained activated until 1h.
Exogenous HGF Modulates Proliferation and Expression
of Sarcomeric Proteins and Connexin43 in Neonatal
Heart
To examine whether the extra-dose of HGF was able to
increase proliferation of cardiac cells, we analyzed Ki67 positive
cells in tissue sections of 7 days-old neonatal hearts. We found a
3-fold increase (p,0.05) in HGF tg mice, compared to controls
(Figure 3A). To confirm that Met receptor stimulation promotes
cardiomyocyte proliferation, we treated the cardiomyoblast cell
line, H9c2, with 10U/ml recombinant HGF in vitro and analyzed
cellular proliferation by means of AlamarBlue assay (Figure 3B)
and BrdU incorporation (Figure 3C). H9c2 cell proliferation
significantly increased after HGF treatment (p,0.005).
In parallel, we analyzed the levels of sarcomeric proteins in
newborn mice. We observed that the levels of cTnT (p,0.005)
and cTnI (p,0.05) were significantly lower in hearts of HGF tg
neonates, as compared to controls (Figure 3D). ssTnI was also
reduced, but the difference between HGF tg and controls was not
significant (Figure 3D). In the adolescent HGF tg mouse, both
cTnT and cTnI proteins were still downregulated (Figure 3E,
p,0.005 and p,0.05, respectively), but reached normal levels in
the adulthood (data not shown). At P18 ssTnI could not be
detected in controls nor in HGF tg mice (not shown). The levels of
both a- and b-MHC were decreased in HGF tg neonates, as
compared to controls (Figure 3D, p,0.05 for a-MHC; p,0.005
for b-MHC). In the adolescent mouse, a-MHC completely
replaced b-MHC, becoming the predominant isoform both in
control and in HGF tg mice (Figure 3E), as described in literature
[6]. We also evaluated the expression levels of the Cx43 protein, a
marker of the working myocardium. In the neonate as well as in
the adolescent, Cx43 protein levels were lower in HGF tg mice,
compared to controls (Figure 3D,E, p,0.005).
HGF Induction in Prenatal Heart Causes Reduced Cardiac
Contractility in the Adult
Adult HGF tg mice were analyzed by echocardiography and
compared with controls. No difference was found between single
transgenics (silent HGF and a-MHC-tTA) and wild-type mice
one day after birth to repress HGF in the postnatal period (prenatal HGF tg mice). (C) Quantitative Real-time PCR of exogenous (upper graph) and
total (endogenous + exogenous) (lower graph) HGF mRNA in fetal (E16.5) and neonatal (P7) heart samples of bitransgenic mice, conceived in the
presence or in the absence of DOX (n = 3 biological replicates). Liver tissue from HGF tg P7 mice was used as a control for the specificity of primers.
(D) Representative Western blot of heart lysates of HGF tg mice with anti-HGF and anti-GFP antibodies. HGF protein migrates as the characteristic
mature a chain of 70 kDa. Erk2 is the loading control. (E) Stereomicroscope images of GFP green fluorescence in neonatal hearts (P7) isolated from
HGF + DOX (left) and HGF tg (right) mice: fluorescence (left panel) and visible plus fluorescence (middle panel); longitudinal tissue section showing
fluorescent GFP+ cardiomyocytes in P7 HGF tg mice (right panel). Bars: 2.5mm (left panel); 250 mm (right panel). (F) mRNA expression of exogenous
HGF in prenatal HGF tg hearts at different post-birth ages.
doi:10.1371/journal.pone.0014675.g001
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Figure 2. Analysis of Met expression and downstream signalling activation in neonatal cardiomyocytes. (A) Immunofluorescence of
Met receptor (red) and GFP (green) in neonatal (P7) heart samples of control (left panel) and HGF tg mice (middle panel). A negative control of
secondary antibody was included (right panel). Bars: 50mm. (B) Western blot of Met (p140Met) protein in control and HGF tg mice at different ages
post-birth (P2 n= 6 n= 7, P4 n= 8 n=6, P7 n= 10 n= 11, P18 n= 9 n=14). Representative blots are shown below densitometric quantification
(normalized on GAPDH loading control, relative to P2 control). Controls vs HGF tg mice: *p,0.05 and {p,0.005 (two-tailed T-test). (C) Densitometric
quantification (normalized on tubulin loading control) and representative Western blot of phospho-Erk1,2 (P Erk1,2), phospho-p38 MAPK (P p38) and
phospho-Akt (P Akt) in HGF tg (n = 7) relative to control mice (n = 6) at two days post birth (P2). *p,0.05 (two-tailed T-test). (D) Western blot analysis
of Met receptor and downstream signalling after treatment of H9c2 cardiomyoblast cell line with 10U/ml of HGF for different lengths of time.
Densitometric quantification was normalized against tubulin and plotted as relative to time 09 of treatment. Each condition was tested 3 times.
doi:10.1371/journal.pone.0014675.g002
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Figure 3. Increased proliferation and reduced expression of sarcomeric proteins and Connexin43 (Cx43) upon HGF induction in
prenatal hearts. (A) Left panel: Quantification of Ki67 positive nuclei in tissue sections of 7 days-old neonatal hearts. Right Ventricle (RV), Left
Ventricle (LV) and Interventricular Septum (IVS) were separately or totally analyzed and compared in controls vs HGF tg neonates (n = 3 animals per
group). At least 5 fields per zone per sample were counted. *p,0.05 (one-tailed T-test). Right panel: Representative Ki67 staining in tissue sections of
7 days-old neonatal hearts of control (left) and HGF tg (right). Ki67: red-nuclear (white arrows). Bar: 100 mm. (B) AlamarBlue assay and (C) BrdU
incorporation of H9c2 cell line not treated (nt) and treated with 10U/ml HGF for the indicated times. Experiments were done in 8 (B) and 2 (C)
biological replicates for each sample group. {p,0.005 versus nt (two-tailed T-test). Right panels: representative IF. BrdU: green-nuclear; propidium
iodide (PI): red-nuclear. Bar: 75 mm. (D,E) Densitometric quantification normalized to Erk2 loading control and representative Western blots of the
indicated proteins. Results represent averaged values for immunoblot analyses performed on heart lysates in (D) P7 neonatal controls (n = 10) vs HGF
tg (n = 11) and (E) P18 young adult controls (n = 9) vs HGF tg (n = 14). Myosin heavy chains (a and b-MHC), troponins (cTnT, cTnI and ssTnI) and Cx43
have been quantified. *p,0.05, {p,0.005 (two-tailed T-test).
doi:10.1371/journal.pone.0014675.g003
Met Signalling in the Heart
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(Table 1). At 100 days of age, HGF tg mice had a significantly
higher left ventricle end systolic diameter (LVESD), in comparison
with controls (Table 1 and Figure 4A) and the fractional
shortening (FS) was significantly reduced (Table 1), suggesting
that an extra-dose of HGF is unfavourable for cardiac contrac-
tility. To distinguish between prenatal and postnatal effects of
HGF stimulation, DOX was not administered to pregnant
mothers and suckling progeny and weaned pups received DOX
starting from postnatal day 1 (prenatal HGF tg mice). At 113 days
of age, also prenatal HGF tg mice showed increased LVESD and
reduced FS (Table 1). This indicated that the extra-dose of HGF
during prenatal life was critical to produce the systolic defect and
that suppression of HGF expression after birth could not rescue
contractile function.
After echocardiographic analysis, bitransgenic animals and
controls were sacrificed and heart/body weight ratios were
measured (Table 1). No significant increase in heart weight and
heart/body weight ratio was observed in any of the bitransgenic
groups (HGF tg and prenatal HGF tg), relative to controls.
Histology of adult bitransgenic hearts and trichrome staining did
not reveal evidence of fibrosis or increased myocyte cross sectional
area (CSA), compared with age-matched controls (Figure S2).
Next, we analysed re-expression of b-MHC, a marker of cardiac
dysfunction. Figure 4B shows higher levels of b-MHC in both
HGF tg and prenatal HGF tg mice (p,0.05), while low protein
level was found in age-matched controls. Furthermore, in the
induced animals, in concomitance with re-expression of b-MHC,
a-MHC appears to be decreased. In both HGF tg and prenatal
HGF tg mice, Cx43 protein expression levels were significantly
decreased also in the adult (Figure 4B, p,0.05). Cx43 is a
component of gap junctions’ channels, which contribute to
communication between adjacent cells. To assess whether the
reduced expression of Cx43 observed in HGF tg mice alters the
permeability of gap junctions, we performed a functional test with
Lucifer yellow. The fluorescent tracer showed significantly
reduced propagation from wound to adjacent cells in HGF tg
mice (Figure 4C, p,0.005).
Induction of Constitutively Activated Met in Postnatal
Cardiomyocytes Causes Reactivation of Fetal Gene
Program and Cardiac Remodeling
We decided to extend observations to another gain-of-function
model produced in our laboratory that, differently from the HGF
tg mouse, allows activation of Met in the absence of the ligand and
cannot be downregulated [22]. The Tpr-Met responder was
crossed with the a-MHC-tTA transactivator to constitutively
activate Met signalling in cardiomyocytes in a cell-autonomous
manner. We found that expression of Tpr-Met in prenatal
development was lethal shortly after birth in 100% of cases.
Bitransgenic Tpr-Met mice were observed with an expected
Mendelian ratio of 25% at E16 (n= 17), E18 (n= 20) and P1
(n= 21), while no viable bitransgenics were found alive at P4
(n= 90). Thus, constitutive activation of Met starting from prenatal
cardiac development leads to death of pups after birth.
To overcome the early lethality of Met hyperactivation and to
evaluate effects of permanent Met activation in postnatal
cardiomyocytes, Tpr-Met mice were conceived and delivered in
the presence of DOX to suppress expression of Tpr-Met during in
utero development. The day following birth, DOX was removed
from drinking water to allow expression of the transgene
(Figure 5A) in postnatal Tpr-Met mice. In the Tet-Off system,
there is no expression at day 0 after the removal of DOX, minimal
expression from days 3 to 7 and maximal expression after day 11
[23]. Transgene expression was verified at both mRNA and
protein levels at P27 (Figure 5A). Postnatal Tpr-Met died at ,4
weeks after birth with signs of congestive heart failure (n = 6),
including lung oedema, alopecia, ascytes, dyspnea and lethargy
(Figure S3). Animals were sacrificed at day 27 and the heart weight
and the heart/body weight ratio were measured. At visual
inspection under the stereomicroscope, Tpr-Met+ hearts showed
impressively enlarged ventricles, with thick ventricular wall and
interventricular septum (Figure 5B). Postnatal Tpr-Met mice had
significantly increased heart mass (0.296 g60.080 vs control
0.160 g60.056, p,0.005) and heart/body weight ratio (2.3 fold
increase, p,0.005), indicating a marked ventricular hypertrophy
Table 1. Echocardiography of HGF tg mice.
wild-type HGF tg prenatal HGF tg silent HGF a-MHC-tTA
(n =11) (n =20) (n=6) (n =9) (n=6)
FS 0.4960.08 0.3460.09* 0.3360.06* 0.4660.07 0.4660.13
IVSTd (mm) 1.13360.181 1.17260.281 1.25960.176 1.12860.116 1.20060.291
LVEDD (mm) 3.77260.402 4.05260.484 3.97060.473 3.86160.371 3.73261.140
PWTd (mm) 1.00960.128 1.00260.232 1.01060.125 0.98160.091 0.97060.130
IVSTs (mm) 1.65460.203 1.60260.414 1.61460.227 1.64860.140 1.63960.455
LVESD (mm) 1.94860.435 2.66360.504* 2.66560.449* 2.11360.456 2.14960.915
PWTs (mm) 1.47660.180 1.37460.305 1.33260.092 1.50260.065 1.39760.189
h/r 0.57160.068 0.53960.115 0.57760.090 0.55060.059 0.63560.223
HW (g) 0.19360.050 0.18260.036 0.22660.031 n.d. n.d.
BW (g) 33.1765.08 32.7163.76 30.3665.76 n.d. n.d.
HW/BW (g/g) 0.00660.001 0.00660.001 0.00760.001 n.d. n.d.
Wild-type: littermate wild-type control; HGF tg: bitransgenic mice conceived in the absence of DOX; prenatal HGF tg: bitransgenic mice treated with DOX at birth and
maintained in DOX thereafter; silent HGF and a-MHC-tTA: littermate single transgenics. FS, fractional shortening; IVSTd, interventricular septum thickness in end
diastole; LVEDD, left ventricle end diastolic diameter; PWTd, posterior wall thickness in end diastole; IVSTs, interventricular septum thickness in end systole; LVESD, left
ventricle end systolic diameter; PWTs, posterior wall thickness in end systole; h/r, heart rate; HW, heart weight; BW, body weight; HW/BW, heart weight/body weight
ratio. n.d., not determined.
*p,0.005 versus wild-type (two-tailed T-test).
doi:10.1371/journal.pone.0014675.t001
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Figure 4. Contractile dysfunction, b-MHC re-expression and decreased Cx43 and cell-cell communication in adult HGF tg and
prenatal HGF tg mice. (A) Representative images of Left Ventricle long-axis echocardiogram (2D and M-Mode) of control (upper panels) and HGF
tg mice (lower panels). (B) Densitometric quantification normalized to Erk2 loading control and representative Western blots of heart ventricles from
control vs HGF tg (upper graph) n = 9 mice per group and prenatal HGF tg (lower graph) n = 3 mice per group. In the latter, HGF expression was
suppressed after birth. Re-expression of b-MHC and decreased Cx43 are evident in both bitransgenic mice compared to controls. *p,0.05 (two-tailed
T-test). (C) Representative images of Lucifer yellow dye diffusion in HGF tg and control edge-cut hearts (upper panels) and zoom-in of the areas
included in dashed boxes (lower panels). Bottom graph: quantification of pixel area showed that cell-to-cell spread of Lucifer yellow was significantly
decreased in HGF tg mice vs controls (n = 3 mice per group). {p,0.005 (one-tailed T-test). Bars: 100mm.
doi:10.1371/journal.pone.0014675.g004
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Figure 5. Induction of activated Met in postnatal cardiomyocytes leads to hypertrophy. (A) Experimental design (left), RT-PCR (middle)
and immunoblot (right) of Tpr-Met expression in postnatal Tpr-Met mice (P27) with Doxycycline (DOX) suppression until birth, compared to controls.
(B) Control and postnatal Tpr-Met hearts were analyzed under stereomicroscopy for comparison (upper panel). Four-chamber cut hearts are also
showed (lower panel). Bars: 5 mm. (C) Significantly increased heart weight (upper graph) and heart/body weight ratio (lower graph) indicate cardiac
hypertrophy in postnatal Tpr-Met mice (n = 6 animals per group). {p,0.005 vs control (two-tailed T-test). (D) Mean cross-sectional area (CSA) of
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(Figure 5C). Consistent with weight measurements, histology of
cardiac tissue and cross sectional area measurements from
postnatal Tpr-Met mice demonstrated increased ventricular
cardiomyocyte size, compared to controls (p,0.005; Figure 5D,E
and Figure S4). Moreover, cardiomyocytes from postnatal Tpr-
Met mice were not only characterized by an increased area, but
also by a high variability in size compared to cardiomyocytes from
control animals (Figure 5D,E and Figure S4), possibly due to
variegated expression of Tpr-Met protein in cardiomyocytes.
Altogether, these results suggest that the hypertrophic phenotype
in Tpr-Met heart may not only involve an increase in cross
sectional area but also myocyte disarray and heterogeneous
volume of the cardiomyocyte population. Only modest signs of
fibrosis were found (data not shown). Reactivation of fetal genes,
frequently associated with hypertrophy and heart failure, was also
observed, with increased ANF and b-MHC mRNA, as detected by
semi-quantitative RT-PCR (Figure 6A). When analyzed in
Western blot, the a- to b isoform switch of MHC, typical of heart
failure, was detected in postnatal Tpr-Met hearts (Figure 6B).
Strong activation of both phospho-Akt and phospho-Erk1,2 was
observed (Figure 6B). Notably, a strong reduction of Cx43 levels
was seen in postnatal Tpr-Met hearts by Western blot and
immunofluorescence analysis (Figure 6B,C and Figure S5),
indicating remodeling of gap junctions. In contrast, mild
upregulation of ZO-1 and no difference in N-Cadherin and b-
Catenin proteins were detected in Western blot (Figure 6B). The
change of Cx43 pattern was detectable already at P15, preceding
the onset of hypertrophy (data not shown).
Discussion
In this article, first we demonstrate that during the early postnatal
period of rapid growth, neonatal cardiomyocytes express the Met
receptor in vivo and can respond to exogenous HGF by activating
downstream signalling. These findings are corroborated in vitro in
H9c2 cardiomyoblast cell line. Second, we show that an extra-dose
of HGF expression (and consequent Met activation) acts on
neonatal cardiomyocytes by influencing both proliferating and
differentiating parameters. The finding that Erk1,2 phosphorylation
is significantly enhanced in HGF-stimulated cardiomyoblasts in vitro
and in neonatal cardiomyocytes of bitransgenic mice in vivo suggests
that the mitogenic activity of HGF arises fromMAPK activation, in
concordance with a previous report [24]. Notably, transition from
hyperplastic to predominant hypertrophic growth in the mouse has
been estimated to happen during the first week after birth [25]. In
our HGF gain-of-function model, at seven days post birth, we found
increased proliferation and decreased sarcomeric protein levels,
indicating that the transition between the plastic phase and the
mature, post-plastic phase was temporally delayed.
It has been shown that cardiomyocyte cell proliferation is
accompanied by a decrease of cell-cell communication [26,27] and
Cx43 has been proposed to contribute to contact inhibition of cell
growth. Accordingly, together with increased proliferation during
postnatal age, we observed markedly low levels of Cx43. This is in
line with previous studies demonstrating that HGF inhibits
intercellular communications via gap junctions in hepatocytes
and keratinocytes [28,29], where it acts as a powerful mitogen.
While the HGF effect on the contractile machinery was limited in
time, Cx43 protein levels were maintained low lifelong. Cx43 was
found to be downregulated even in adult mice with HGF
expression suppressed the day following birth. This suggests that
an imperfect organization of cell-cell communication during
development triggers a functional defect that cannot be subse-
quently reversed during adult life. Remodeling of gap junctions
has been observed in a variety of cardiomyopathic conditions,
including hibernating myocardium, infarction and dilated cardio-
myopathy [30]. Observations in ischemic and hibernating heart
disease have led to the thesis that gap junction remodeling may
contribute not only to defects in electrical signal conduction, but
also to impairment of contractile force [31]. To date, evidence
linking gap junction remodeling with ventricular dysfunction has
been correlative, with the exception of studies done on chimeric
mice, composed of variable mixtures of Cx43-null and wild-type
cells throughout all tissues of the body [32]. These mice showed no
morphological abnormalities, myocardial fibrosis or hypertrophy,
but developed significant systolic dysfunction. Mechanistically, in
our gain-of-function model, regional dysregulation of Cx43 in
cardiomyocytes, due to excessive activation of the HGF/Met
system during development, could lead to a loss of coordinated
contraction throughout the heart wall and, consequently, local
increased systolic wall stress and ventricular dysfunction. We
propose that alteration of growth specifically in the fetal/neonatal
heart and/or of intercellular communication may prime it to
develop an increased susceptibility to disease.
The inducible character of our HGF mouse model demonstrates
that prenatal development is the specific stage influenced by
activation of Met signalling. In fact, at 3 months of age our HGF tg
mice developed a contractile defect, even when HGF expression
was suppressed after birth. This result is consistent with the finding
that the endogenous Met receptor is physiologically downregulated
in terminally differentiated cardiomyocytes, making the system
insensitive to further HGF stimulation. The high susceptibility of
prenatal age to Met stimulation is further confirmed by the fact that
expressing Tpr-Met instead of HGF starting from prenatal age was
lethal soon after birth. The Tpr-Met fusion protein lacks the
extracellular, transmembrane and juxtamembrane domains of Met
receptor and has gained the Tpr dimerization motif, which allows
constitutive and ligand-independent activation of the kinase. The
loss of juxtamembrane sequences necessary for the negative
regulation of kinase activity and receptor degradation prolongs
duration of Met signalling [22]. For this reason, the Tpr-Met model
represents a very strong gain-of-function model of Met activation
and yields an exacerbated cardiac defect with respect to the HGF
model. Hypoxia and growth restriction are well described causes of
developmental origin of cardiovascular disease. Ligand-indepen-
dent Met overexpression is induced by the hypoxia inducible factor-
1 (HIF-1) [33] and by depletion of von Hippel-Lindau protein,
which is responsible for suppressing HIF-1 levels during normoxia
[34]. Hypoxia and Met itself are responsible for inducing an
adaptive process known as invasive growth through which the
organism attains homeostasis, in particular foraging for supplies for
cell survival, such as oxygen and glucose. We propose that an
alteration of Met signalling, such as HGF/Met overexpression,
giving a message of nutrition or oxygen restriction, could mimic the
molecular effect of these environmental cues. Such a trigger could
ventricular cardiomyocytes is significantly higher in postnatal Tpr-Met compared to controls (left panel). n = 300 cells from 3 biological replicates per
group. {p,0.005 vs control (two-tailed T-test). Distribution curves (right panel) of counted CSA show a shift to the right side in postnatal Tpr-Met
mice as respect to controls. (E) Representative transversal sections of left ventricles show increased size in postnatal Tpr-Met cardiomyocytes. Left
panels: laminin (red-surface). Right panels: quadruple overlay with laminin (red- surface), Griffonia (blue-endothelial), DAPI (white-nuclear) and GFP
(green-intracellular). Bars: 35mm.
doi:10.1371/journal.pone.0014675.g005
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Figure 6. Tpr-Met expressing hearts show fetal gene re-expression and remodeling of Cx43. (A) Semi-quantitative RT-PCR analysis of
controls and postnatal Tpr-Met mice (P27) showed re-expression of ANF and b-MHC mRNA. Tubulin is used as loading control. (B) a to b isoform
switch of MHC, increased phosphorylation of downstream Akt and Erk1,2 and strongly decreased Cx43, mild increase of ZO-1 and normal N-Cadherin
and b-Catenin levels in postnatal Tpr-Met vs control hearts, analyzed by Western blot. Densitometric quantification normalized on Akt loading control
and representative blots below graphs are shown. n = 10 mice for each group. *p,0.05 and {p,0.005 vs control (two-tailed T-test) (C) Left panels:
representative confocal immunofluorescence images of left ventricle sections from postnatal Tpr-Met mice showed decreased staining of Cx43 (red),
compared to controls (upper panels). Bottom panels: quadruple overlay with Cx43: red; a-actinin: blue; DAPI: white-nuclear; GFP: green-intracellular;
Bars: 35mm. Quantification of Cx43 staining was performed with ImageJ. n = 6 controls and n= 3 postnatal Tpr-Met mice.
doi:10.1371/journal.pone.0014675.g006
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induce an adaptive response pathway, which would be maintained
over time through an epigenetic footprint. It will be interesting to
investigate whether elevatedMet receptor levels have a putative role
in the etiology of hypoxia-initiated cardiac disease.
Sustained activation of Tpr-Met in postnatal cardiomyocytes (1
to 4 weeks) leads to increased cross sectional area of cardiomy-
ocytes, reactivation of fetal gene program, increased cardiac mass
and, ultimately, to lethal congestive heart failure at P28. Thus, the
constitutive activation of Tpr-Met gives to the cell a signal of
growth, which, in terminally differentiated cardiomyocytes, results
in switching on a hypertrophic program. Both Ras/RAF/MEK/
ERK and Akt pathways, which are downstream to Met and Tpr-
Met, are known to be involved in the growth promotion and
protection of cardiomyocytes from apoptosis. However, their
contribution in defining ‘‘physiological’’ versus ‘‘pathological’’
growth is still controversial. In the HGF model, the low level of
Met receptor, which cannot be superinduced by HGF stimulation
in the terminally differentiated cardiomyocyte, cannot shift the
equilibrium to hypertrophic growth. Interestingly, in the postnatal
Tpr-Met model we found only mild signs of interstitial fibrosis,
albeit pathological hypertrophic growth is usually associated with
scar tissue formation. This finding confirms the antifibrotic action
of HGF/Met activation, which has been demonstrated in a variety
of tissues, including the heart [35].
Tpr-Met expression induced a dramatic decrease in Cx43
protein levels in postnatal cardiomyocytes. This reinforces the
concept that Met receptor activation acts negatively on cell-cell
communication, albeit the precise mechanism by which this
suppression is mediated awaits elucidations. Evidence is in favour
of the view that both formation and maintenance of gap junctions
is critically dependent on the presence of correct mechanical
stabilization [36]. The interdependence between mechanical and
electrical junctions seems to be unilateral, since the absence of
Cx43 does not change the structure of intercalated discs with
respect to adherens junctions, as shown in an animal model with
cardiac-specific conditional knockout of Cx43 [37]. This seems to
be the case of our study, since both Tpr-Met and HGF-activated
Met signalling in cardiomyocytes maintain connexins in a
remodeled state, with Cx43 being downregulated at the protein
level and removed from end-to-end intercalated discs. Meanwhile
proteins constituting adherens junctions show no quantitative
abnormalities, though a slight increase of cell adhesion proteins
has been observed in heart of postnatal Tpr-Met mice. The
changes in Cx43 pattern distribution were seen at a fairly early
stage in the disease progress, suggesting that Cx43 may be an early
indicator of cardiac stress.
In conclusion, our mouse models support the idea that HGF/
Met stimulation promotes cardiomyocyte growth. Although other
studies have suggested that HGF may have a beneficial function in
pathological conditions, such as ischemic injury, there are no
experimental evidences in the current study to demonstrate that
enhancement of HGF/Met signalling is favourable in a physio-
logical setting. On the other hand, excessive HGF/Met signalling
in prenatal period may raise adverse effects and might be linked to
the pathogenesis of progressive cardiac disease.
Supporting Information
Figure S1 Neonatal HGF tg hearts show no morphological
defects. Haematoxylin-eosin staining of four-chamber cut sections
of P7 control (left) and HGF tg (right) hearts. Bars: 2mm.
Found at: doi:10.1371/journal.pone.0014675.s001 (0.88 MB TIF)
Figure S2 No signs of fibrosis nor hypertrophy were found in
adult HGF tg mice. (A) Trichrome staining does not show fibrosis
in either control or littermate HGF tg mice at 4 months of age. (B)
Cross-sectional area of myocytes was not different between control
and HGF tg mice at 4 months of age (green-surface: laminin;
green-intracellular: GFP; blue-nuclear: DAPI; red-endothelial:
Griffonia). Bars: 50 mm (A); 75mm (B).
Found at: doi:10.1371/journal.pone.0014675.s002 (3.14 MB TIF)
Figure S3 Postnatal Tpr-Met mice at P27 display signs of
congestive heart failure. (A) Tpr-Met mice exhibit dyspnea and
lethargy. Extensive oedema and haemorrhage of Tpr-Met lungs
shown by haematoxylin and eosin staining of lung tissue (B),
stereomicroscopy inspection (C) and lung weight measurement
(D), compared to littermate controls. n = 4 animals per group.
* p,0.01 vs control (two-tailed T-test). Bars: 20mm (A); 100mm
(B); 5mm (C).
Found at: doi:10.1371/journal.pone.0014675.s003 (1.23 MB TIF)
Figure S4 Single immunofluorescence stainings of quadruple
overlay shown in Figure 5E: Laminin (red-surface), Griffonia
(blue-endothelial), DAPI (white-nuclear), GFP (green-intracellular)
and 4 colours merge. Bars: 35 mm.
Found at: doi:10.1371/journal.pone.0014675.s004 (2.67 MB TIF)
Figure S5 Single immunofluorescence stainings of quadruple
overlay shown in Figure 6E: Cx43 (red), a-actinin (blue), DAPI
(white-nuclear), GFP (green-intracellular) and 4 colours merge.
Bars: 35 mm.
Found at: doi:10.1371/journal.pone.0014675.s005 (2.66 MB TIF)
Table S1 Primers used throughout the study.
Found at: doi:10.1371/journal.pone.0014675.s006 (0.31 MB
PDF)
Table S2 List of antibodies used in this study.
Found at: doi:10.1371/journal.pone.0014675.s007 (0.59 MB
PDF)
Acknowledgments
We gratefully acknowledge Sokol Kalaja for animal care, Marco Demaria
for technical help in Real time-PCR and Guido Serini for Confocal
Imaging with TCS SP2 AOBS. We also thank Stefano Gatti and Simona
Gallo for technical assistance and Giovanni Losano for useful comments
and critical reading of the manuscript.
Author Contributions
Conceived and designed the experiments: CL VS IR DM TC. Performed
the experiments: CL VS MM AC IR DM. Analyzed the data: CL VS MM
AC IR DM TC. Contributed reagents/materials/analysis tools: DM SS
CP TC. Wrote the paper: VS TC.
References
1. Porrello ER, Widdop RE, Delbridge LMD (2008) Early Origins of Cardiac
Hypertrophy: Does Cardiomyocyte Attrition Programme for Pathological
‘Catch-Up’ Growth of the Heart? Clin Exp Pharmacol Physiol 35: 1358–1364.
2. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ (1989) Weight in
infancy and death from ischaemic heart disease. Lancet 2: 577–580.
3. Li FQ, Wang XJ, Capasso JM, Gerdes AM (1996) Rapid transition of cardiac
myocytes from hyperplasia to hypertrophy during postnatal development. J Mol
Cell Cardiol 28: 1737–1746.
4. Schiaffino S, Gorza L, Ausoni S (1993) Troponin Isoform Switching in the Developing
Heart and its Functional Consequences. Trends Cardiovasc Med 3: 12–17.
5. Siedner S, Kruger M, Schroeter M, Metzler D, Roell W, et al. (2003)
Developmental changes in contractility and sarcomeric proteins from the early
embryonic to the adult stage in the mouse heart. J Physiol-London 548: 493–505.
6. Lyons GE, Schiaffino S, Sassoon D, Barton P, Buckingham M (1990)
Developmental regulation of myosin gene expression in mouse cardiac muscle.
J Cell Biol 111: 2427–2436.
Met Signalling in the Heart
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e14675
7. Hirschy A, Schatzmann F, Ehler E, Perriard JC (2006) Establishment of cardiac
cytoarchitecture in the developing mouse heart. Dev Biol 289: 430–441.
8. Boccaccio C, Comoglio PM (2006) Opinion - Invasive growth: a MET-driven
genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637–645.
9. Moumen A, Ieraci A, Patane S, Sole C, Comella JX, et al. (2007) Met signals
hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3K-
Akt-dependent manner. Hepatology 45: 1210–1217.
10. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, et al. (2000)
Myocardial protection from ischemia/reperfusion injury by endogenous and
exogenous HGF. J Clin Invest 106: 1511–1519.
11. Ueda H, Nakamura T, Matsumoto K, Sawa Y, Matsuda H, et al. (2001) A
potential cardioprotective role of hepatocyte growth factor in myocardial
infarction in rats. Cardiovasc Res 51: 41–50.
12. Urbanek K, Rota M, Cascapera S, Bearzi C, Nascimbene A, et al. (2005)
Cardiac stem cells possess growth factor-receptor systems that after activation
regenerate the infarcted myocardium, improving ventricular function and long-
term survival. Circ Res 97: 663–673.
13. Rappolee DA, Iyer A, Patel Y (1996) Hepatocyte growth factor and its receptor
are expressed in cardiac myocytes during early cardiogenesis. Circ Res 78:
1028–1036.
14. Song W, Majka SM, McGuire PG (1999) Hepatocyte growth factor expression
in the developing myocardium: evidence for a role in the regulation of the
mesenchymal cell phenotype and urokinase expression. Dev Dyn 214: 92–100.
15. Zammit PS, Kelly RG, Franco D, Brown N, Moorman AF, et al. (2000)
Suppression of atrial myosin gene expression occurs independently in the left
and right ventricles of the developing mouse heart. Dev Dyn 217: 75–85.
16. Giacobini P, Messina A, Wray S, Giampietro C, Crepaldi T, et al. (2007)
Hepatocyte growth factor acts as a motogen and guidance signal for
gonadotropin hormone-releasing hormone-1 neuronal migration. J Neurosci
27: 431–445.
17. Crepaldi T, Bersani F, Scuoppo C, Accornero P, Prunotto C, et al. (2007)
Conditional activation of MET in differentiated skeletal muscle induces atrophy.
J Biol Chem 282: 6812–6822.
18. Yu Z, Redfern CS, Fishman GI (1996) Conditional transgene expression in the
heart. Circ Res 79: 691–697.
19. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, et al. (1991)
Morphological, biochemical, and electrophysiological characterization of a
clonal cell (H9c2) line from rat heart. Circ Res 69: 1476–1486.
20. Naitoh K, Ichikawa Y, Miura T, Nakamura Y, Miki T, et al. (2006)
MitoK(ATP) channel activation suppresses gap junction permeability in the
ischemic myocardium by an ERK-dependent mechanism. Cardiovasc Res 70:
374–383.
21. Feigenbaum H, Armstrong WF, Ryan T (2005) Evaluation of systolic and
diastolic function of the left ventricle Feigenbaum’s Echocardiography.
Lippincott Williams & Wilkins.
22. Peschard P, Park M (2007) From Tpr-Met to Met, tumorigenesis and tubes.
Oncogene 26: 1276–1285.
23. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, et al. (1999)
Conditional expression and signaling of a specifically designed G(i)-coupled
receptor in transgenic mice. Nat Biotechnol 17: 165–169.
24. Maillet M, Purcell NH, Sargent MA, York AJ, Bueno OF, et al. (2008) DUSP6
(MKP3) Null Mice Show Enhanced ERK1/2 Phosphorylation at Baseline and
Increased Myocyte Proliferation in the Heart Affecting Disease Susceptibility.
J Biol Chem 283: 31246–31255.
25. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KDR, et al. (2001)
Myocardial Akt activation and gender - Increased nuclear activity in females
versus males. Circ Res 88: 1020–1027.
26. Doble BW, Dang XT, Ping PP, Fandrich RR, Nickel BE, et al. (2004)
Phosphorylation of serine 262 in the gap junction protein connexin-43 regulates
DNA synthesis in cell-cell contact forming cardiomyocytes. J Cell Sci 117:
507–514.
27. Kardami E, Doble BW (1998) Cardiomyocyte gap junctions: A target of growth-
promoting signaling. Trends Cardiovasc Med 8: 180–187.
28. Ikejima K, Watanabe S, Kitamura T, Hirose M, Miyazaki A, et al. (1995)
Hepatocyte growth factor inhibits intercellular communication via gap junctions
in rat hepatocytes. Biochem Biophys Res Commun 214: 440–446.
29. Moorby CD, Stoker M, Gherardi E (1995) Hgf/Sf Inhibits Junctional
Communication. Exp Cell Res 219: 657–663.
30. Severs NJ, Bruce AF, Dupont E, Rothery S (2008) Remodelling of gap junctions
and connexin expression in diseased myocardium. Cardiovasc Res 80: 9–19.
31. Kaprielian RR, Gunning M, Dupont E, Sheppard MN, Rothery SM, et al.
(1998) Downregulation of immunodetectable connexin43 and decreased gap
junction size in the pathogenesis of chronic hibernation in the human left
ventricle. Circulation 97: 651–660.
32. Gutstein DE, Morley GE, Vaidya D, Liu F, Chen FL, et al. (2001)
Heterogeneous expression of Gap junction channels in the heart leads to
conduction defects and ventricular dysfunction. Circulation 104: 1194–1199.
33. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, et al. (2003)
Hypoxia promotes invasive growth by transcriptional activation of the met
protooncogene. Cancer Cell 3: 347–361.
34. Lei L, Mason S, Liu DG, Huang Y, Marks C, et al. (2008) Hypoxia-inducible
factor-dependent degeneration, failure, and malignant transformation of the
heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol 28:
3790–3803.
35. Taniyama Y, Morishita R, Aoki M, Hiraoka K, Yamasaki K, et al. (2002)
Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomy-
opathy. Hypertension 40: 47–53.
36. Ferreira-Cornwell MC, Luo Y, Narula N, Lenox JM, Lieberman M, et al. (2002)
Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing
cadherins in the heart. J Cell Sci 115: 1623–1634.
37. Gutstein DE, Liu FY, Meyers MB, Choo A, Fishman GI (2003) The
organization of adherens junctions and desmosomes at the cardiac intercalated
disc is independent of gap junctions. J Cell Sci 116: 875–885.
Met Signalling in the Heart
PLoS ONE | www.plosone.org 14 February 2011 | Volume 6 | Issue 2 | e14675
